WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) reported a widening third-quarter loss as the Wayne-based biotechnology company increased spending on clinical development and commercial preparations ahead of a Feb. 28, 2027, FDA decision on its experimental treatment for a rare, lifelong vascular disorder.
The company recorded a net loss of $24.6 million, or $1.70 per share, for the quarter ended Sept. 30, 2026, compared with $11.3 million, or $1.03 per share, a year earlier.
The U.S. Food and Drug Administration has accepted Palvella’s New Drug Application for QTORIN rapamycin to treat microcystic lymphatic malformations and granted it priority review, establishing a regulatory decision deadline of Feb. 28, 2027.
If approved, the topical treatment could become the first FDA-approved therapy specifically for microcystic lymphatic malformations, a rare condition affecting an estimated 30,000 or more diagnosed children and adults in the United States.
Palvella is preparing for an independent U.S. commercial launch during the first half of 2027, contingent on FDA approval. The company has established commercial, medical and patient support capabilities and is expanding its workforce ahead of the potential introduction.
The regulatory milestone places Palvella within months of a potential transition from a clinical-stage biotechnology company to a commercial drug developer.
Palvella held $236.7 million in cash, cash equivalents and short-term investments as of Sept. 30, providing capital for its regulatory, clinical and commercial activities.
Research and development expenses increased to $10.8 million in the third quarter from $6.5 million a year earlier.
The increase reflected manufacturing activities, clinical development of QTORIN rapamycin for angiokeratomas, completion of the rolling regulatory application for microcystic lymphatic malformations, and higher staffing and consulting costs.
General and administrative expenses rose to $11.9 million from $3.6 million, driven by increased headcount and professional services associated with operating as a publicly traded company.
The higher spending accompanies an expanding clinical program built around Palvella’s QTORIN platform, which develops topical formulations for rare dermatologic diseases and vascular anomalies.
The company’s lead program targets microcystic lymphatic malformations, which can cause persistent skin lesions, fluid leakage, bleeding and other complications.
Palvella presented additional findings from its Phase 3 SELVA trial at dermatology conferences during 2026, including patient-reported clinical benefits and treatment satisfaction.
Data presented at the Pediatric Dermatology Research Alliance Annual Conference showed improvements among pediatric participants in overall disease severity, lesion height, vesicle appearance, and leaking or bleeding.
Additional findings showed that systemic exposure to rapamycin remained low and stable over 24 hours, with mean exposure at least 40 times lower than levels reported with oral sirolimus.
The FDA’s Office of Orphan Products Development also awarded a third year of grant funding to support the SELVA trial and its ongoing open-label extension study.
Palvella founder and Chief Executive Officer Wes Kaupinen identified regulatory approval and commercialization of QTORIN rapamycin as the company’s immediate priorities.
“Our focus is clear: successfully obtain FDA approval and bring our first therapy to patients, advance multiple additional QTORIN programs to approval,” Kaupinen stated.
Beyond its lead indication, Palvella is preparing to begin a Phase 3 trial of QTORIN rapamycin for cutaneous venous malformations during the fourth quarter of 2026.
Results presented from the Phase 2 TOIVA study showed improvements in overall disease severity and reduced lesion bleeding among pediatric patients receiving the treatment.
The company is also enrolling patients in LOTU, a multicenter Phase 2 trial evaluating QTORIN rapamycin for clinically significant angiokeratomas.
The FDA has granted the program Fast Track designation. Palvella estimates that more than 50,000 diagnosed U.S. patients have the condition, for which no FDA-approved treatment currently exists.
Top-line results from LOTU are expected in the second half of 2027.
A separate development program is evaluating QTORIN pitavastatin for disseminated superficial actinic porokeratosis, or DSAP, a chronic skin disorder.
Palvella presented an analysis of U.S. health insurance claims identifying approximately 154,986 diagnosed DSAP patients nationwide.
A Phase 2 trial of QTORIN pitavastatin is scheduled to begin during the fourth quarter of 2026.
The company also plans to identify another clinical indication for QTORIN rapamycin and disclose a third product candidate from its development platform before the end of 2026.
Palvella is expanding its medical leadership as it approaches the FDA decision.
James R. Treat, MD, is scheduled to become chief medical officer on Dec. 21, 2026.
Treat is a pediatric dermatologist with nearly two decades of clinical, research and academic experience, including work involving cutaneous vascular anomalies. He previously served as an investigator in Palvella’s Phase 3 SELVA trial and a Phase 2 study of QTORIN rapamycin.
The company also reported that Chief Scientific Officer Jeff Martini, Ph.D., was selected to provide public comment at an FDA workshop examining regulatory and scientific approaches to repurposing existing medicines for rare diseases.
Palvella had 15,844,715 shares outstanding as of Nov. 2, including 14,618,457 common shares and 1,226,258 common share equivalents associated with outstanding pre-funded warrants.
The company’s near-term operating strategy centers on securing FDA approval for QTORIN rapamycin while advancing additional clinical indications that could broaden its commercial portfolio.
The February regulatory decision will determine whether Palvella can proceed with its planned U.S. launch in the first half of 2027, following a year of increased spending on product development, staffing and commercialization.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.